Neulasta (pegfilgrastim), a new long-acting form of Neupogen (filgrastim)

Amgen will soon launch Neulasta (pegfilgrastim), a new long-acting form of Neupogen (filgrastim).

It's a new option for preventing infection in chemo patients. Neulasta and Neupogen stimulate the production of white blood cells.

Neulasta is made by attaching polyethylene glycol (PEG) to filgrastim. The "pegylated" version is cleared more slowly so it can be given less often.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote